Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial

Gavin Brittain(Sheffield Teaching Hospitals NHS Foundation Trust), John A. Snowden(Sheffield Teaching Hospitals NHS Foundation Trust), Cindy Cooper(Department of Health and Social Care), Paolo A. Muraro(Imperial College Healthcare NHS Trust), Richard Nicholas(Swansea University), Elisa Roldán(Sheffield Teaching Hospitals NHS Foundation Trust), Alasdair Coles(University of Cambridge), Matthew Bursnall(University of Sheffield), Thushan I. de Silva(Sheffield Teaching Hospitals NHS Foundation Trust), Diana Papaioannou(University of Sheffield), David Paling(Royal Hallamshire Hospital), Eli Silber(King's College Hospital NHS Foundation Trust), Olga Ciccarelli(Queen Mary University of London), Andy Peniket(Churchill Hospital), Rachel Glover(University of Sheffield), Neil Scolding(University of Bristol), Katie Hullock(University of Sheffield), Stephen J. Walters(University of Sheffield), Jennifer Petrie(University of Aberdeen), Kate E. M. Duffy(University of Sheffield), Carolyn Young(University of Liverpool), Charalampia Kyriakou(The Royal Free Hospital), Annalena Venneri(University of Parma), Majid Kazmi, Ian Gabriel(Imperial College London), Basil Sharrack(Sheffield Teaching Hospitals NHS Foundation Trust), Colette Beecher(Sheffield Hallam University), Gavin Giovannoni(Queen Mary University of London)
BMJ Open
February 1, 2024
Cited by 10


Related Papers